Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

@article{Kjeldsen2008ProgressiveEO,
  title={Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial},
  author={Sverre E. Kjeldsen and Gordon T. Mcinnes and Giuseppe Mancia and Tsushung A. Hua and Stevo Julius and Michael A. Weber and Antonio Coca and Xavier Girerd and Kenneth A. Jamerson and Pierre Larochelle and Thomas Macdonald and Roland E. Schmieder and M. Anthony Schork and Reuven J. Viskoper and Jiř{\'i} Widimsk{\'y} and Alberto Zanchetti and FOR THE VALUE TRIAL INVESTIGATORS},
  journal={Blood Pressure},
  year={2008},
  volume={17},
  pages={170 - 177}
}
We have previously shown that the angiotensin receptor blocker valsartan is associated with a lower incidence of new‐onset type 2 diabetes than that with the calcium‐channel antagonist amlodipine in the treatment of hypertensive patients at high cardiovascular risk. We have now investigated the benefits of valsartan vs amlodipine in patients of different categories of diabetogenic risk. Some 9995 patients without diabetes at onset participated in VALUE, with average follow‐up of 4.2 years… 
Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients.
TLDR
There is sufficient evidence that ARBs have beneficial effect in preventing new-onset type 2 diabetes, and ARBs should be considered in patients with high risk of developing diabetes.
Effect of valsartan on insulin resistance in patients with hypertension: a systematic review and meta-analysis
Objective: The aim of the present meta-analysis was to evaluate the effect of valsartan on insulin resistance in patients with hypertension. Methods: We searched the electronic databases, including
Comparison of real-world effectiveness between valsartan and non-RAS inhibitor monotherapy on the incidence of new diabetes in Chinese hypertensive patients: An electronic health recording system based study
TLDR
Compared with non-RAS inhibitors, particularly CCBs, valsartan could significantly reduce the incidence of NOD.
Effects of antihypertensive treatments on incidence of diabetes: A case-control study
TLDR
Diuretics seem to be associated with a higher incidence of diabetes, whereas treatment with ACEi/ARB could have a protective effect, according to a case-control study nested within a cohort of non-diabetic subjects.
Antihypertensive treatment in diabetic patients. Review of current data.
TLDR
Current data support initiation of antihypertensive drug treatment in all patients with diabetes and systolic BP ≥ 140 mmHG, with the aim to lower it consistently <140 mmHg, although how far below 140mmHg the syStolic BP goal should be is not clear.
Olmesartan medoxomil-based therapy for the management of hypertension
TLDR
Olmesartan medoxomil-based therapy can manage hypertension across a range of patient types and has demonstrated good BP-lowering efficacy and goal attainment in individuals with stage 1 or stage 2 hypertension.
Antihypertensive Treatment in Type 2 Diabetic Patients
TLDR
The present chapter focuses on the most recent and significant literature that explored the possible pathogenetic links between essential hypertension and type 2 diabetes, and it reviews the evidences for "optimal" antihypertensive treatment in type 2 diabetic patients and concomitant hypertension, discussing in detail some areas of uncertainty.
[Prevention of diabetes mellitus type 2].
TLDR
This work critically review here the current situation of the disease and shows that prevention of DM2 is possible, despite the increasing prevalence worldwide.
Prediabetes: The Importance of Early Identification and Intervention
TLDR
The pathophysiology of prediabetes and its clinical implications are discussed, highlighting the importance of early identification and intervention.
Angiotensin II receptor antagonists in acute coronary syndromes
TLDR
Evidence form basic research and clinical studies, investigating the efficacy of angiotensin II receptor blockers (ARBs) in the management of acute coronary syndromes (ACS) is discussed.
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
TLDR
Treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine, and reduces the risk of developing diabetes mellitus in high-risk hypertensive Patients.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
TLDR
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period, which emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial
TLDR
The randomized population is now being treated (goal blood pressure < 140/90 mmHg) in adherence with the protocol until at least 1450 patients experience primary cardiac endpoint defined as clinically evident or aborted myocardial infarction, hospitalization for heart failure or death caused by coronary heart disease.
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
TLDR
New-onset diabetes could be strongly predicted by a newly developed risk score using baseline serum glucose concentration (non-fasting), body mass index, serum high-density lipoprotein cholesterol concentration, systolic blood pressure and history of prior use of antihypertensive drugs.
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
TLDR
The data indicate that compared with doxazosin, chlorthalidone reduces the risk of combined CVD events, particularly CHD death/nonfatal MI, in high-risk hypertensive patients.
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial
TLDR
G glucose and BMI were the most important predictors of new-onset diabetes mellitus in hypertensive patients at high cardiovascular risk, and easily accessible clinical characteristics strongly predict patients at risk of developing diabetes mell Titus.
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
TLDR
Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine).
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
TLDR
Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
TLDR
Diltiazem was as effective as treatment based on diuretics, beta-blockers, or both in preventing the combined primary endpoint of all stroke, myocardial infarction, and other cardiovascular death.
Old antihypertensives and new diabetes
TLDR
When compared with placebo, ACE inhibition by ramipril or by the ARB, candesartan, both decrease the incidence of new diabetes, raising the hypothesis that these agents actually prevent the changes leading to insulin resistance, possibly by lessening the adverse effects of angiotensin II on the endothelium.
...
1
2
3
4
...